630 - A 5-mRNA host response whole-blood classifier trained using patients with non-COVID-19 viral infections accurately predicts severity of COVID-19

The ePoster content is available to users who are logged in.<br><br>Please log in and then come back here to use this button.

Co-Author(s)

lB

ljubomir Buturovic

VP
Inflammatix
Burlingame, California
Disclosure: Inflammatix Inc. (Employee, Shareholder)
PK

Purvesh Khatri

ASsociate Professor
Stanford University
Stanford, California
Disclosure: Inflammatix Inc. (Shareholder)
BT

Benjamin Tang

Associate Professor
Nepean Hospital
Sydney, New South Wales, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
KL

Kevin Lai

Attending
Westmead Hospital
Sydney, New South Wales, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
WK

Win Sen Kuan

Attending
National University Hospital Singapore
singapore, Singapore
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MG

Mark Gillett

Attending
Royal North Shore Hospital
Sydney, New South Wales, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
RS

Rahul Santram

Attending
St Vincent Hospital
Sydney, New South Wales, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MS

Maryam Shojaei

Dr
WESTMEAD INSTITUTE FOR MEDICAL RESEARCH
Sydney, New South Wales, Australia
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
RA

Raquel Almansa

Dr.
HURH-IBSAL
valladolid, Castilla y Leon, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
JN

Jose Nieto

Attending
Servicio de Urgencias de Atención Primaria
Salamanca, Castilla y Leon, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SM

Sonsoles Muñoz

att
Servicio de Urgencias de Atención Primaria
Salamanca, Castilla y Leon, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
CH

Carmen Herrero

Attending
Servicio de Urgencias de Atención Primaria
Salamanca, Castilla y Leon, Spain
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
NA

Nikolaos Antonakos

MD, PhD, Internal Medicine specialist
4th Department of Internal Medicine, ATTIKON University Hospital
Athens, Attiki, Greece
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
PK

Panayiotis Koufargyris

Clinical Chemist
National and Kapodistrian University of Athens, Medical School, Greece
Athens, Attiki, Greece
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
MK

Marina Kontogiorgi

Attending
14. 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, 124 62 Athens, Greece
Athens, Attiki, Greece
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
GD

Georgia Damoraki

Systems Biologist
National Expertise Center of Greece in Autoimmune Liver Diseases
Athens, Attiki, Greece
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presenting Author(s)

Oliver Liesenfeld

CMO
Inflammatix
Sunnyvale, CA
Disclosure: Inflammatix Inc. (Employee, Shareholder)

Co-Author(s)

JW

James Wacker

Biostatistician
Inflammatix
Burlingame, California
Disclosure: Inflammatix Inc. (Employee, Shareholder)
UM

Uros Midic

Sr Machine Learning Scientist
Inflammatix Inc
Burlingame, California
Disclosure: Inflammatix Inc. (Employee, Shareholder)
RL

Roland Luethy

Sr. Machine Learning Scientist
Burlingame
Burlingame, California
Disclosure: Inflammatix Inc. (Employee, Shareholder)
DR

David C. Rawling

Director
Inflammatix
Burlingame, California
Disclosure: Inflammatix Inc. (Employee, Shareholder)
MR

Melissa Remmel

Staff Scientist
Inflammatix
Burlingame, CA
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
SC

Sabrina Coyle

Research Associate II
Inflammatix, Inc.
Burlingame, California
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
EG

Evangelos J. Giamarellos-Bourboulis

Professor of Internal Medicine, Director: Master (MSc) Program of Infectious Diseases
National and Kapodistrian University of Athens, Medical School
Athens, Attiki, Greece
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
TS

Timothy Sweeney

CEO
Inflammatix, Inc
Burlingame, California
Disclosure: Inflammatix, Inc. (Employee, Shareholder)

Background: While major progress has been made to establish diagnostic tools for the diagnosis of SARS-CoV-2 infection, determining the severity of COVID-19 remains an unmet medical need. With limited hospital resources, gauging severity would allow for some patients to safely recover in home quarantine while ensuring sicker patients get needed care. We discovered a 5 host mRNA-based classifier for the severity of influenza and other acute viral infections and validated the classifier in COVID-19 patients from Greece.

Methods: We used training data (N=705) from 21 retrospective clinical studies of influenza and other viral illnesses. Five host mRNAs from a preselected panel were applied to train a logistic regression classifier for predicting 30-day mortality in influenza and other viral illnesses. We then applied this classifier, with fixed weights, to an independent cohort of subjects with confirmed COVID-19 from Athens, Greece (N=71) using NanoString nCounter. Finally, we developed a proof-of-concept rapid, isothermal qRT-LAMP assay for the 5-mRNA host signature using the QuantStudio 6 qPCR platform.

Results: In 71 patients with COVID-19, the 5 mRNA classifier had an AUROC of 0.88 (95% CI 0.80-0.97) for identifying patients with severe respiratory failure and/or 30-day mortality (Figure 1). Applying a preset cutoff based on training data, the 5-mRNA classifier had 100% sensitivity and 46% specificity for identifying mortality, and 88% sensitivity and 68% specificity for identifying severe respiratory failure. Finally, our proof-of-concept qRT-LAMP assay showed high correlation with the reference NanoString 5-mRNA classifier (r=0.95).Figure 1. Validation of the 5-mRNA classifier in the COVID-19 cohort. (A) Expression of the 5 genes used in the logistic regression model in patients with (red) and without (blue) mortality. (B) The 5-mRNA classifier accurately distinguishes non-severe and severe patients with COVID-19 as well as those at risk of death.

Conclusion: Our 5-mRNA classifier demonstrated very high accuracy for the prediction of COVID-19 severity and could assist in the rapid, point-of-impact assessment of patients with confirmed COVID-19 to determine level of care thereby improving patient management and healthcare burden.